HRP20200423T1 - Kombinirana terapija - Google Patents
Kombinirana terapija Download PDFInfo
- Publication number
- HRP20200423T1 HRP20200423T1 HRP20200423TT HRP20200423T HRP20200423T1 HR P20200423 T1 HRP20200423 T1 HR P20200423T1 HR P20200423T T HRP20200423T T HR P20200423TT HR P20200423 T HRP20200423 T HR P20200423T HR P20200423 T1 HRP20200423 T1 HR P20200423T1
- Authority
- HR
- Croatia
- Prior art keywords
- phosphate
- alaninyl
- gemcitabine
- benzoxy
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/054158 WO2017109444A1 (en) | 2015-12-23 | 2015-12-23 | Combination therapy |
| GBGB1609770.1A GB201609770D0 (en) | 2016-06-03 | 2016-06-03 | Combination therapy |
| PCT/GB2016/054018 WO2017109486A1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
| EP16820005.3A EP3393478B1 (en) | 2015-12-23 | 2016-12-21 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200423T1 true HRP20200423T1 (hr) | 2020-09-04 |
Family
ID=57681677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200423TT HRP20200423T1 (hr) | 2015-12-23 | 2016-12-21 | Kombinirana terapija |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20190022117A1 (enExample) |
| EP (2) | EP3738595A1 (enExample) |
| JP (1) | JP6898329B2 (enExample) |
| KR (1) | KR20180096698A (enExample) |
| CN (1) | CN108697725A (enExample) |
| AU (1) | AU2016375861B2 (enExample) |
| CA (1) | CA3008749C (enExample) |
| CY (1) | CY1122835T1 (enExample) |
| DK (1) | DK3393478T3 (enExample) |
| EA (1) | EA037459B1 (enExample) |
| ES (1) | ES2778933T3 (enExample) |
| HR (1) | HRP20200423T1 (enExample) |
| HU (1) | HUE050290T2 (enExample) |
| IL (1) | IL260076A (enExample) |
| LT (1) | LT3393478T (enExample) |
| MA (1) | MA51576A (enExample) |
| MD (1) | MD3393478T2 (enExample) |
| ME (1) | ME03677B (enExample) |
| MX (1) | MX383988B (enExample) |
| MY (1) | MY194629A (enExample) |
| PH (1) | PH12018501339A1 (enExample) |
| PL (1) | PL3393478T3 (enExample) |
| PT (1) | PT3393478T (enExample) |
| RS (1) | RS60211B1 (enExample) |
| SG (1) | SG11201805184TA (enExample) |
| SI (1) | SI3393478T1 (enExample) |
| SM (1) | SMT202000154T1 (enExample) |
| WO (1) | WO2017109486A1 (enExample) |
| ZA (1) | ZA201804155B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013346515B2 (en) | 2012-11-16 | 2017-05-25 | NuCana plc | Process for preparing nucleoside prodrugs |
| EA033046B1 (ru) | 2014-06-25 | 2019-08-30 | НУКАНА ПиЭлСи | Состав, содержащий пролекарство гемцитабина |
| RS60968B1 (sr) | 2014-06-25 | 2020-11-30 | NuCana plc | Prolekovi gemcitabina |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| PH12018500691B1 (en) | 2015-10-05 | 2022-08-10 | NuCana plc | Combination therapy |
| CA3007347C (en) | 2015-12-11 | 2020-08-04 | NuCana plc | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| EA201491629A1 (ru) * | 2012-08-13 | 2015-08-31 | Регулон, Инк. | Способы лечения рака с использованием липоплатина |
| JP6420247B2 (ja) * | 2012-11-13 | 2018-11-07 | ボーイエン セラピューティクス，インコーポレイティド | ゲムシタビンプロドラッグ及びその使用 |
| CN107835687A (zh) * | 2015-05-14 | 2018-03-23 | 努卡那有限公司 | 癌症治疗 |
| PH12018500691B1 (en) * | 2015-10-05 | 2022-08-10 | NuCana plc | Combination therapy |
-
2016
- 2016-12-21 SI SI201630680T patent/SI3393478T1/sl unknown
- 2016-12-21 CN CN201680082464.9A patent/CN108697725A/zh active Pending
- 2016-12-21 EA EA201891473A patent/EA037459B1/ru unknown
- 2016-12-21 CA CA3008749A patent/CA3008749C/en active Active
- 2016-12-21 PT PT168200053T patent/PT3393478T/pt unknown
- 2016-12-21 HU HUE16820005A patent/HUE050290T2/hu unknown
- 2016-12-21 EP EP20160070.7A patent/EP3738595A1/en not_active Withdrawn
- 2016-12-21 MD MDE20181039T patent/MD3393478T2/ro not_active IP Right Cessation
- 2016-12-21 US US16/065,498 patent/US20190022117A1/en not_active Abandoned
- 2016-12-21 WO PCT/GB2016/054018 patent/WO2017109486A1/en not_active Ceased
- 2016-12-21 KR KR1020187020533A patent/KR20180096698A/ko not_active Ceased
- 2016-12-21 MY MYPI2018001015A patent/MY194629A/en unknown
- 2016-12-21 DK DK16820005.3T patent/DK3393478T3/da active
- 2016-12-21 ES ES16820005T patent/ES2778933T3/es active Active
- 2016-12-21 ME MEP-2020-56A patent/ME03677B/me unknown
- 2016-12-21 SM SM20200154T patent/SMT202000154T1/it unknown
- 2016-12-21 MX MX2018007772A patent/MX383988B/es unknown
- 2016-12-21 HR HRP20200423TT patent/HRP20200423T1/hr unknown
- 2016-12-21 RS RS20200297A patent/RS60211B1/sr unknown
- 2016-12-21 AU AU2016375861A patent/AU2016375861B2/en not_active Ceased
- 2016-12-21 SG SG11201805184TA patent/SG11201805184TA/en unknown
- 2016-12-21 PL PL16820005T patent/PL3393478T3/pl unknown
- 2016-12-21 JP JP2018532746A patent/JP6898329B2/ja not_active Expired - Fee Related
- 2016-12-21 MA MA051576A patent/MA51576A/fr unknown
- 2016-12-21 EP EP16820005.3A patent/EP3393478B1/en active Active
- 2016-12-21 LT LTEP16820005.3T patent/LT3393478T/lt unknown
-
2018
- 2018-06-17 IL IL260076A patent/IL260076A/en unknown
- 2018-06-21 ZA ZA2018/04155A patent/ZA201804155B/en unknown
- 2018-06-21 PH PH12018501339A patent/PH12018501339A1/en unknown
-
2020
- 2020-03-17 CY CY20201100245T patent/CY1122835T1/el unknown
-
2022
- 2022-06-21 US US17/845,878 patent/US20230149436A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| JP2019509253A5 (enExample) | ||
| HRP20251261T1 (hr) | Inhibitori csf1r za uporabu u liječenju tenosinovijalnih gigantocelularnih tumora | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| JP2019536805A5 (enExample) | ||
| HRP20250480T1 (hr) | Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća | |
| JP2015038135A5 (enExample) | ||
| JP2019524690A5 (enExample) | ||
| HRP20180455T1 (hr) | Natrijev (2r, 5s, 13ar) -7, 9-diokso-10- ( (2,4,6-trifluorobenzil) karbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-oktahidro-2, 5-metanopirido [1’,2’ : 4.5]pirazino [2,1-b]oksazepin-8-olat | |
| JP2014528423A5 (enExample) | ||
| WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
| JP2020523356A5 (enExample) | ||
| ME02395B (me) | Kombinovana terapija sa antitumorskim alkaloidima | |
| JP2023533464A5 (enExample) | ||
| HRP20212030T1 (hr) | Kombinacija koja sadrži palbociklib i 6-(2,4-diklorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-8,9-dihidro-7h-benzo[7]anulen-2-karboksilnu kiselinu i njezina upotreba u liječenju raka | |
| JP2020523354A5 (enExample) | ||
| JP2013231087A5 (enExample) | ||
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| JP2020523359A5 (enExample) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| HRP20251214T1 (hr) | Pripravci za liječenje i/ili prevenciju bolesti agregacije proteina | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| PH12018501339A1 (en) | Combination therapy | |
| BR112019002513A2 (pt) | uso e dosagem de agentes terapêuticos para endometriose | |
| JP2015507020A5 (enExample) |